Genetic Technologies Limited

Registered Office
60-66 Hanover Street
Fitzroy
Victoria
3065

Tel: 61-3-9415-1135
Fax: 61-3-9417-2987

Email: info@gtg.com.au

Show jobs for this employer

139 articles with Genetic Technologies Limited

  • Molecular diagnostics company Genetic Technologies Limited is pleased to announce an interview with its interim-CEO, Dr. Jerzy Muchnicki aired on The RedChip Money Report television program.

  • Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, Dr. Jerzy Muchnicki, will share insight into the company’s recent developments during an investor webinar on Thursday, November 19, 2020 at 4:15 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation. To participate in the webinar, please register at: https://www.redchip.com/cor

  • Molecular diagnostics company Genetic Technologies Ltd, provides the following update to the market on the development of the Company’s COVID-19 Risk Test.

  • Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 1,025,000 American Depositary Shares (“ADSs”)

  • Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,025,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $5.00 pe

  • Highlights Genetic Technologies has filed a provisional patent for its COVID-19 Severity Risk Test with the Patent Office in Australia The COVID-19 Severity Risk Test comprises a polygenic risk test (PRS) and assessment for clinical risk factors Genetic Technologies has completed the design and request for initial production of the SNP (Single Nucleotide Polymorphism) panel required to process the polygenic risk test portion of the COVID-19 Severity Risk Test from US-based Thermo Fisher Sc

  • Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
  • Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its interim-CEO Dr. George Muchnicki will share insight into the Company’s recent developments during an investor webinar, hosted by RedChip Companies, on Wednesday, June 24, 2020 at 4:00 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation.

  • Molecular diagnostics company Genetic Technologies Limited is pleased to announce the issuance of US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer.

  • Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced public offering of 3,500,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS,

  • Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS (or ADS equivalent). The closing of the offering is expected to

  • Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) provides the following operational updates: Normal commercial operations will recommence from 1 June 2020 Confirmed that a prototype polygenic risk score can successfully discriminate between COVID-19 patients who required hospitalization from those who did not require hospitalization Continued discussions with third parties around use of existing CLIA and NATA accr

  • Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to predict an individual’s risk of developing life-threatening complications should they become infected with COVID-19. Dr George Muchnicki CEO said " GENE has secured a data set of over 1,500 patients who experienced COVID-19 and we intend on leveraging our core expertise in predictive risk modelling, to a

  • Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 722,502 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $2.00 per ADS for gross proceeds of approximately $1.44 million. H.C. Wainwright &

  • Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 722,502 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $2.00 per

  • Genetic Technologies Limited has developed a detailed implementation plan to enable a temporary transition of our genetic testing laboratory to a high-throughput COVID-19 testing laboratory, should it be required by Government agencies to assist with demand.

  • Genetic Technologies Limited announced the closing of the previously announced registered direct offering of 1,028,574 American Depositary Shares, each representing six hundred of the Company’s ordinary shares, at a purchase price of $1.75 per ADS.

  • Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market. Breast Cancer and Colorectal Cancer tests commissioned, and sales commenced First Quarter 2020 with over 100 test kits distributed. Early data generated from tests identified a number of high-risk individuals leading to personalised care plans designed for early detection Consumer Initiated Tes

  • Genetic Technologies Limited announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,028,574 American Depositary Shares, each representing six hundred of the Company’s ordinary shares, at a purchase price of $1.75 per ADS.

  • Genetic Technologies Limited announced that after the close of the ASX market on March 13, 2020, it received a determination letter from The Nasdaq Stock Market LLC indicating that it did not comply with the Listing Rule 5550 for continued listing on the Nasdaq Capital Market